En

October 9, 2019

Bicyclo[1.1.1]pentane (BCP) is emerging as an interesting fragment in medicinal chemistry. It serves as a bioisostere for a phenyl or tert-butyl group. Due to the SP3 hybridization of the structures, it is considered to generate drug-like molecules with good passive permeability, high aqueous solubility, and improved metabolic stability.  BCP derivatives are already a pharmaceutically important scaffold. However, large scale preparation of BCP is still considered synthetically challenging. This webinar is going to review the medicinal application of the BCP in discovery new drug candidates, its metabolism and review new synthetic development to generate complex BCP derivatives in the recent literature. This webinar will be delivered by Dr Charles Chen from Bellen Chem who are kindly sponsoring this session.

For more information contact: 

October 12-16, 2019
Barcelona, Spain

Molecular imaging is continuously expanding: it is increasingly being combined with advanced technologies such as artificial intelligence and has become a principal component of medical imaging. In the therapy field, targeted radiopharmaceuticals have been demonstrated to be effective and are increasingly used in a variety of clinical settings, often integrated with other therapeutic options. The ultimate goal is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine clinical practice.

In the last three years, the status of the EANM annual meeting as the world-reference congress in nuclear medicine has been confirmed. In order to maintain the high level of excellence, the 2019 EANM Congress will build on the traditions that are highly appreciated by all attendees, with the expansion of newer features. A specific educational track, implemented with the collaboration of the European School of Multimodality Imaging and Therapy, will include up-to-date teaching sessions, enriched pitfalls seminars and Continuous Medical Education interactive sessions. In all these active learning conferences, attendees will have the possibility to enhance their knowledge of multimodality imaging. A careful evaluation procedure relating to the speakers will be implemented in order to gain feedback and ensure that future interactive sessions continue to enjoy a positive response. With similar pedagogic intent, numerous multidisciplinary joint symposia, organised by several EANM Committees in collaboration with our sister societies, will offer an integrative approach to various topics relevant to the state of the art of our discipline.

For more information contact: office@eanm.org

October 16, 2019

One of the most difficult parts of discovering a drug is the optimization of pharmacokinetic properties.  Drug hunters must be mindful of ADME (absoprtion, distribution, metabolism and excretion) properties to insure that drug candidates have adequate drug exposures across preclinical species and ultimately humans.  Frequently, drug candidates are highly metabolized, limiting exposure to the drug target tissue.  Thus, mitigation of metabolism issues is one of the most impactful ways to improve the pharmacokinetic profile of a drug candidate.  This webinar will describe the most common drug metabolizing enzymes (DMEs) and metabolic pathways encountered in drug discovery.  Importantly, it will also highlight the assays and mitigation strategies in use to profile, understand and optimize the metabolism of drug candidates.  Other important principles, such as minimizing the formation of reactive metabolites and the impact of cytochrome p450 (CYP) inhibitors/activators on drug-drug interactions (DDIs) will also be described.

While the focus is on medicinal chemistry methods, this webinar will benefit all scientists who participate in the cross functional execution of drug discovery programs.

This FREE webinar will be presented by Dr Bryan Norman.

For more information contact: 

October 29, 2019
Zagreb, Croatia

Contact person: Vesna Gabelica Markovic
Email: Vesna.gabelica.markovic@hkd.hr


EFMC Sponsored Event

November 20, 2019
Nottingham, United Kingdom

It has been over twenty years since Lipinski published his work determining the properties of drug molecules associated with good solubility and permeability. Since then, there have been a number of additions and expansions to these “rules”. There has also been keen interest in the application of these guidelines in the drug discovery process and how these apply to new emerging chemical structures such as macrocycles. 

This symposium will bring together researchers from a number of different areas of drug discovery and will provide a historical overview of the use of Lipinski’s rules, as well as looking to the future and how we use these rules in the changing drug compound landscape. 

Features of the Meeting

  • Historical look at the use of the Rule of Five
  • New parameters used in drug discovery
  • Look forward to the next 20 years
  • Panel discussions in each session
  • Plenary speakers, poster session, and drinks reception

For more information please contact: 


EFMC Sponsored Event

November 22, 2019
Brussels, Belgium

The Medicinal Chemistry Divisions of the two Belgian Chemical Societies, the Koninklijke Vlaamse Chemische Vereniging (KVCV) and the Société Royale de Chimie (SRC), are organising every year an international one-day symposium with the aim to update participants on selected areas of pharmaceutical research by specialists in their respective field. 

MedChem 2019 will be held on Friday November 22, 2019, in Brussels. The programme of the day will include six invited lectures and three oral communications selected from submitted abstracts.

This year, the symposium will delve into the developments in the therapeutic use of peptides.

Confirmed Speakers:

  • Prof. Fernando ALBERICIO (UNIVERSITY OF KWAZULU-NATAL, Durban , South Africa)
    Linkers for Peptide Conjugation
  • Prof. Christian F.W. BECKER (UNIVERSITY OF VIENNA, Wien, Austria)
    Synthetic Immune System Engagers – a Peptide-based Approach to Immune-oncology
  • Prof. Eric MARSAULT (UNIVERSITY OF SHERBROOKE, Sherbrooke, Canada)
    Macrocyclization as an Enabling Tool Toward Novel Peptide Drug Candidates
  • Prof. Kristian STROMGAARD (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark) 
    Targeting Receptor Complexes: A New Dimension in Drug Discovery
  • Dr Meritxell TEIXIDO (INSTITUTE FOR RESEARCH IN BIOMEDICINE, Barcelona, Spain)
    Gate2Brain, Opening the Gate to CNS Therapies

Deadline for abstract submission and early bird fee is October 10, 2019!

For more information please contact: secretariat@ldorganisation.com

Organised by:
  • Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) (Belgium)
  • Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)

December 10-11, 2019
Veldhoven, The Netherlands

Contact person: Dr Ingrid Dijkgraaf
Tel: +31 43 3881681
Fax: +31 43 3884159
Email:

December 11, 2019
Paris, France

Contact person: Dr Brigitte LESUR
Tel: +33 (0) 1 55 72 26 16
Email: or

Organised by:
  • Société de Chimie Thérapeutique (France)

December 11, 2019
Paris, France

The French Society of Medicinal Chemistry (Société de Chimie Thérapeutique – SCT) is pleased to invite you to Paris, on December 11th, 2019 for the 4th one-day thematic symposium focusing on the contribution of Chemical Biology to Molecular Therapeutic Innovations.

The aim of the symposium is to illustrate the great potential and applications of RNA-targeting modalities in contributing to therapeutic innovation.
This meeting is dedicated to a large audience of organic and medicinal chemists, biochemists and biologists from academic and industry. During this day, we will focus on recent advances in the field of RNA targeting using small molecules as well as oligonucleotides: the synthetic challenges involved in the design of RNA-targeting agents and on the validation of relevant RNA targets, as well as on the current methodologies used to study RNA/ligands interactions. RNA has already been drugged. Ribosomal RNA was drugged serendipitously with natural product antibiotics and later linezolid. A design-driven approach to drugging RNA was achieved with antisense oligonucleotides (ASOs) and then by RNA interference (RNAi) mechanisms.
More recently, small molecules that bind to the FMN riboswitch and to SMN2 pre-mRNA were reported and are close to clinical application. All those recent developments in the field of RNA-targeting definitely hold promise for future therapeutic applications.

Confirmed Speakers:

  • Matthew DISNEY (Scripps, Florida, USA)
    Translating RNA Sequence Into Lead Small Molecule Medicines
  • Maria DUCA (Université Côte d’Azur, France)
    Synthetic Small-Molecule RNA Ligands : Scope and Applications
  • Mélanie ETHEVE-QUELQUEJEU (Université de Paris, France)
    Modified RNAs as Molecular Tools for Structural and Functional Studies of RNAs dependents Enzymes
  • Eric ENNIFAR (Université de Strasbourg, France) 
    Structure-Guided Discovery of Novel Ligands Targeting the HIV-1 Genomic Viral RNA
  • Jonathan HALL (ETH Zürich, Switzerland)
    A Bright Future for Oligonucleotide Drugs
  • Gerhard MUELLER (Gotham Therapeutics, Germany)
    Epitranscriptomic Readers, Writers, and Erasers: a Biophysics and Medicinal Chemistry Perspective
  • Alleyn PLOWRIGHT (Sanofi-Aventis Deutschland GmbH, Germany)
    Modulating RNA - Recent Drug Discovery Approaches and Opportunities for Diverse Modalities
  • Helene TRAN (Servier Research Institute, France)
    Antisense Oligonucleotides Therapeutics for CNS Disorders

For more information please contact: secretariat@sct-asso.fr

December 13, 2019
Cambridge, United Kingdom

The Biological and Medicinal Chemistry Sector (BMCS) of the RSC will be hosting its 13th postgraduate symposium for PhD students and postdoctoral workers researching in biological or medicinal chemistry and related areas. The event will be held in the Department of Chemistry at the University of Cambridge on Friday 13th December 2019. Researchers working in these areas are invited to participate. Registration will start at 9:00 am with talks beginning at 10:00 am. The day will consist of 11 oral presentations (8 student and 3 keynote) plus a Flash Poster section. Each 20 minute student talk will be followed by 10 minutes for questions.

Throughout the day there will be keynote talks from industrial and academic chemists. A buffet lunch will be provided to accompany the poster session. The BMCS judges will be awarding prizes to participants. There will be prizes of £500 for the best oral presentation and of £250 for the best poster and these will be celebrated at the end of the day.

If you are interested in presenting your relevant PhD or post-doctoral work please submit a half-page abstract by 17th September 2019 in addition to registering. Those selected by the BMCS committee to give oral presentations will be notified by 27th October. Travel expenses will be reimbursed to all speakers.

This event is FREE but all attendees should register as soon as possible and no later than by Saturday, 30th November 2019.

Online registration form: http://bit.ly/2Ui6Eqd

For queries and abstract submission contact Dave Alker at dave.alker@btinternet.com


EFMC Sponsored Event

January 19-23, 2020
St. Anton, Austria

The “Alpine Winter Conference on Medicinal and Synthetic Chemistry” exposes attending scientists to cutting edge synthetic and medicinal chemistry as well as latest developments in technologies that foster innovation in drug discovery. The main target audience for this highly interdisciplinary meeting will include medicinal and synthetic chemists, as well as related drug discovery disciplines from both industry and academia as well as graduate/undergraduate students and postdocs.

In the spirit of Keystone and Gordon conferences as well as the MBCF (Medicinal and Bioorganic Chemistry Foundation) conference in Steamboat Springs, the format of this meeting provides ample opportunity for attendees to informally interact. The aim is to strengthen existing networks and create new contacts.

The Conference topics will include:

  • Accelerating Drug Discovery by Intelligence Augmentation
  • Drug Discovery Tales
  • Frontiers of Synthetic Chemistry
  • Innovation and Inspiration from Natural Products
  • Predictive ADME Sciences: Striking a Balance Between in Silico and Experimental Work?
  • Protein Degradation: New Rules for Drug Discovery
  • Structure and Biophysics - Companions for Medicinal Chemistry
  • Targeted Delivery - Strategies to Help your Drug Substances get to the Right Place

Deadline for abstract submission and early bird fee is October 16, 2019!

For more information please contact: secretariat@ldorganisation.com

January 22-24, 2020
Geneva, Switzerland

The NCCR Chemical Biology is organising the 2020 International Symposium on Chemical Biology to be held from January 22 to 24, 2020 at Campus Biotech in Geneva. This international meeting of high scientific calibre will bring together leading scientists to feature the latest advances within the broad field of Chemical Biology and foster an open and dynamic dialogue!

New international collaborations and increased international visibility will hopefully be the outcome of this unique learning experience that comprises extensive poster sessions, ample time for discussion after each talk and opportunities for targeted networking.

Three hundred participants from Swiss universities, various research institutes in Switzerland and neighbouring countries are expected to attend.

Registration will close on December 16, 2019.

The number of participants is limited to 300.

For more information contact nccr-chembio@unige.ch

March 22-26, 2020
Philadelphia, Pennsylvania

ACS organizes two national meetings & expositions each year, and each one attracts an estimated 11,000 to 13,000 chemists, chemical engineers, academicians, graduate and undergraduate students, and other related professionals. During the meeting, scientists present new multidisciplinary research, hear the latest information in their areas of professional interest, and network with colleagues. Programming is planned by our 33 technical divisions that cover all scientific fields, secretariats that focus on multidisciplinary programming, and ACS committees. Each meeting will feature more than 7,000 presentations organized into technical symposia that highlight important research advances with over 250 exhibitors showcasing new technological developments.

Contact person: Vanessa L. Johnson-Evans
Email:


EFMC Sponsored Event

April 14-15, 2020
San Francisco, United States

The identification of potential new therapeutic agents is met with significant challenges in preclinical discovery and development.  Both efficacy and safety endpoints must be adequately assessed prior to testing a new investigational agent in humans.  Perhaps the most challenging part of drug discovery is the mitigation of safety risks that arise during most drug discovery optimization efforts.  In order to design and make safer drug candidates, medicinal chemists work with cross-functional drug discovery partners to understand, assess and mitigate safety risks associated with potential new drug candidates.  Successful drug discovery teams will properly design and execute experiments that can best assess and discharge risks prior to first human dose (FHD).  This must be accomplished in the context of anticipated human drug exposures and patient risk-benefit analysis.  Through the lens of modern medicinal chemistry, this course explores the current best practices and methods used to identify, understand and mitigate common preclinical safety risks from both a strategic and tactical perspective.  Importantly, the course also describes proactive approaches that can help medicinal chemists avoid many safety issues and deliver safer small molecule drug candidates.  A key objective of the course is to improve medicinal chemist’s preparedness for participation and leadership on cross-functional drug discovery teams.

Course Outline:

  • Principles of toxicology and safety assessment.
  • The Investigational New Drug (IND) application.
  • Target assessment, predictive toxicology and in silico methods.
  • Preferred drug properties to minimize toxicological risks.
  • Common off-target safety concerns and mitigation.
  • Managing on-target safety concerns.
  • Pharmacokinetics in preclinical safety assessment.
  • Drug metabolism and bioactivation.
  • Toxicophores and Structure Alerts.
  • Mechanisms and mitigation strategies for Drug-Induced Liver Injury (DILI).
  • Preclinical safety biomarkers and translation to the clinic.
  • Clinical candidate selection and FHD enablement.

For more information contact: 

August 23 - 27, 2020
San Francisco, California

ACS organizes two national meetings & expositions each year, and each one attracts an estimated 11,000 to 13,000 chemists, chemical engineers, academicians, graduate and undergraduate students, and other related professionals. During the meeting, scientists present new multidisciplinary research, hear the latest information in their areas of professional interest, and network with colleagues. Programming is planned by our 33 technical divisions that cover all scientific fields, secretariats that focus on multidisciplinary programming, and ACS committees. Each meeting will feature more than 7,000 presentations organized into technical symposia that highlight important research advances with over 250 exhibitors showcasing new technological developments.

Contact person: Vanessa L. Johnson-Evans
Email:


EFMC Symposium

September 6-10, 2020
Basel, Switzerland

The XXVI EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2020) is organised by the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society (SCS), on behalf of the European Federation for Medicinal Chemistry (EFMC).

The symposium will take place in Basel from September 6-10, 2020.

The 2020 edition will continue the tradition established for these biennial symposia of covering advances in drug discovery in major therapeutic areas, including the treatment of bacterial and viral infections, diseases related to the CNS, heart disease, fibrotic diseases and cancer.

EFMC-ISMC 2020 will also present most recent advances in highly topical areas such as, for example, the application of artificial intelligence in drug discovery and in synthesis, carbohydrate recognition and drug design, the targeting of RNA, small molecule-induced stem cell differentiation, and the impact of cryo-EM on drug discovery and design. In a series of Chemical Biology sessions, the interface between chemical biology and drug discovery will be highlighted by discussing the use of chemical probes for target discovery, aspects of molecular imaging, and photochemical approaches. In response to frequent requests by attendees of previous conferences, several sessions will be dedicated to advances in synthetic methodology for drug discovery. Finally, particular emphasis will again be put on first time disclosures and recent highlights in medicinal chemistry.

The EFMC is the main organisation for the European Medicinal Chemistry community, with 26 member societies and about 7.500 members. Its biennial EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery and it traditionally attracts around 1.000 participants both from industry and academia. The last 5 EFMC-ISMC meetings took place in Belgium (Brussels, 2010), Germany (Berlin, 2012), Portugal (Lisbon, 2014), in the United Kingdom (Manchester, 2016), and Slovenia (Ljubljana, 2018).

We look forward to welcoming you in Basel in September!

Organised by:
  • Division for Medicinal Chemistry & Chemical Biology (DMCCB) (Switzerland)
  • European Federation of Medecinal Chemistry (EFMC)


EFMC Symposium

September 10-11, 2020
Basel, Switzerland

The EFMC Young Medicinal Chemist Symposium is an initiative of the European Federation for Medicinal Chemistry (EFMC). After a successful first edition organised in Lisbon in September 2014, four further meetings have been organised in Antwerp (2015), Manchester (2016), Vienna (2017), Ljubljana (2018) and Athens (2019). The 7th edition will be organised in connection with the EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2020), and will take place in Basel on September 10-11, 2020.

This short symposium has the aim of:

  • creating a network of young European investigators in Medicinal Chemistry
  • stimulating young European investigators in Medicinal Chemistry to share their scientific work with peers and inspiring leaders in the field
  • creating competition and excellence in Medicinal Chemistry within Europe by selecting the European Champion in Medicinal Chemistry

Stay tuned as more information will be added soon!

March 21-25, 2021
San Antonio, Texas

June 16-18, 2021
Denmark

August 22-26, 2021
Atlanta, Georgia


EFMC Symposium

August 29 - September 2, 2021
Zagreb, Croatia
Organised by:
  • Croatian Chemical Society, Section of Medicinal/Pharmaceutical Chemistry (Croatia)
  • European Federation of Medecinal Chemistry (EFMC)

September 26-29, 2019
Brazil

March 20-24, 2022
San Diego, California

August 21-25, 2022
Chicago, Illinois


EFMC Symposium

September 4-8, 2022
Nice, France
Organised by:
  • Société de Chimie Thérapeutique (France)
  • European Federation of Medecinal Chemistry (EFMC)

March 26-30, 2023
Indianapolis, Indiana

August 13-17, 2023
San Francisco, California

March 17-21, 2024
New Orleans, Louisianna

August 18-24, 2024
Denver, Colorado

March 23-27, 2025
San Diego, California

August 17-21, 2025
Washington, District of Columbia